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Abstract
Background: Familial amyloidosis with polyneuropathy (FAP) is an autosomal dominant disease caused by
transthyretin (TTR) mutations, of which V30M (TTR c.148G > A, p.Val50Met, “Val30Met”) is the most common.
Swedish V30M carriers display later age at onset and lower penetrance compared to other populations.
Methods: In the study, 130 Swedish V30M carriers (32 early, 30 late onset and 68 asymptomatic carriers) and 50
controls, 23 French symptomatic V30M carriers and 29 controls and 18 Japanese symptomatic V30M carriers and 29
controls were included. We aimed to identify additional genetic factors in the TTR gene and its surrounding region
that could have an impact on phenotype.
Results: We identified three SNPs (rs71383038, rs3794885 and rs62093482) with a significant difference in allele
frequency between Swedish V30M carriers and controls. The two Swedish V30M homozygous patients present in
the study also displayed homozygosity for the CA10 (rs71383038), A (rs3794885) and T (rs62093482) alleles in these
SNPs. Hence, these alleles are present on the Swedish V30M haplotype. Of these, rs62093482 is located in the 3′
UTR of TTR gene and thus more interesting since SNPs in the 3′UTR can affect gene expression levels by modifying
microRNA (miRNA) targeting activity. miRNA target predictions revealed four potential miRNAs with predicted
targets unique for the polymorphic allele.
Conclusions: Our results are the first to show the presence of a 3′UTR polymorphism on the V30M haplotype in
Swedish carriers, which can serve as a miRNA binding site potentially leading to down-regulated expression from
the mutated TTR allele. This finding may be related to the low penetrance and high age at onset of the disease
observed in the Swedish patient population.
Background
Familial amyloidosis with polyneuropathy (FAP, OMIM
+176300) is a fatal autosomal dominant disease caused
by mutations in the TTR gene. TTR encodes transthyr-
etin, a circulating and abundant tetramer that func-
tions as a carrier protein of thyroid hormone and
retinol binding protein. Transthyretin is mainly pro-
duced in the liver, but also in the brain and eye. Muta-
tions in TTR cause the protein to dissociate into
monomers that after misfolding assemble into amyloid
fibrils deposits in a diversity of organs [1]. The main
clinical symptom of FAP is progressive sensory-motor
peripheral neuropathy, often associated with auto-
nomic disturbances. Gastrointestinal dysfunction, renal
failure and heart involvement with restrictive-hyper-
trophic cardiomyopathy and/or conduction distur-
bances are common complications. Genetically, FAP
is a heterogeneous disease with approximately 100
amyloidogenic TTR missense mutations currently
described. The most common TTR mutation V30M
(“Val30Met”, c.148G > A, p.Val50Met) is found spora-
dically worldwide, but also in endemic areas of Portu-
gal, Japan and Sweden [2]. For V30M carriers there is
considerable phenotypic variability both between and
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anticipation has been observed in families in the Swed-
ish endemic area [3,4]. Northern Sweden has a high
V30M carrier frequency (1.5% [5]) with an exception-
ally low penetrance (5% before the age 40 [4]) and a
high median age at onset, 56 years [5], leading to low
incidence and prevalence. The French V30M popula-
tion also exhibits low penetrance [6]. In contrast, ende-
mic areas in Portugal have ten times lower carrier
frequency than northern Sweden (0.18%, [7]), but the
high penetrance (87% before the age 40 [8]) and early
age at onset, 33 years [7], leads to high incidence and
prevalence of the disease. Even though marked differ-
ences in phenotype are noted, haplotype analysis of the
TTR gene region disclosed that Swedish V30M FAP
patients all share a common founder [9]. A similar
investigation of the French FAP population identified
the presence of several founders for the TTR V30M
mutation (Violaine Plante-Bordeneuve, CHU Henri
Mondor, France, Personal communication). Portuguese
and Japanese patients appear to share a common foun-
der between the two populations [9,10]. No difference
in disease penetrance has been noted between homozy-
gous and heterozygous V30M carriers [11]. Unexpect-
edly, homozygous Swedish V30M carriers do not have
am o r ea g g r e s s i v ed i s e a s et h a nt h a to fh e t e r o z y g o t e
V30M carriers.
The observed phenotypic variations among carriers of
the same mutation indicate that additional, still
unknown, genetic and epigenetic factors have an impact
on phenotype and penetrance of this autosomal domi-
nant trait. The two main aims of the present study were
i) to identify additional genetic variants in the TTR gene
and its surrounding region that might influence the phe-
notype of the disease with regards to age at onset and
penetrance in northern Sweden, and ii)t oc o m p a r e
these TTR gene variants between different populations.
To address this, we compared allele frequencies for
Swedish V30M FAP patients, asymptomatic V30M
carriers and controls, and also Swedish with French and
Japanese V30M FAP patients and controls.
Methods
Subjects and DNA samples
Swedish material
Sixty-two FAP TTR V30M patients referred for diagnos-
tic testing at Clinical Genetics, University Hospital of
Umeå, Sweden, between 1987 and 2007 were included
in the study. Their FAP diagnose was based on presence
of clinical symptoms consistent with the diagnosis, amy-
loid deposits in biopsy samples and the TTR V30M
mutation. Patients were selected to represent two age at
onset groups. In the early onset group (before age 40,
n = 32), the mean age at onset was 32.0 ± 5.0 years,
whereas the late-onset group (after age 50, n = 30)
presented an average onset of 78.6 ± 6.1 years. Since
1986, all inhabitants in the County of Västerbotten in
northern Sweden are invited to a health examination the
year they turn 40, 50 and 60 years. Blood samples are
collected and stored in The Northern Sweden Health
and Disease Study (NSHDS) Cohort. From this cohort
3460 DNA samples were genotyped for the V30M allele,
identifying 63 asymptomatic V30M carriers. All V30M
carriers that since their contribution to the NSHDS
cohort developed symptomatic FAP were excluded.
Since all blood samples were obtained from individuals
at the age of 60, and had been stored up to 10 years
before they were analysed, we defined them as asympto-
matic carriers. In addition, five asymptomatic V30M
carriers present in the local FAP registry at the Depart-
ment of Medicine were included, yielding in total 68
asymptomatic V30M carriers. The total number of TTR
V30M carriers, both patients and asymptomatic carriers
was 130. Fifty controls matched for age, geographical
origin and gender were selected from the NSHDS
cohort.
French material
DNA samples from 23 V30M FAP patients, with an age
at onset between 29 and 74 years (55.6 ± 14.6), and 29
healthy controls were obtained from Department of
Molecular Biology, CHU Bicêtre, Le Kremlin Bicêtre,
France.
Japanese material
DNA samples from 18 V30M FAP patients, age at onset
between 23 and 61 years (36.5 ± 12.1), and 29 healthy
controls were obtained from the Department of Neurol-
ogy, Kumamoto University Hospital, Kumamoto, Japan.
Methods
DNA was extracted according to standard protocols. Gen-
otyping of DNA samples from the NSHDS cohort was
performed with mutation specific MGB probes, PCR and
endpoint analysis (custom made TaqMan genotyping
assay, probe and primer sequences available on request).
In the Swedish material, all four TTR exons with a flank-
ing intron/exon region of minimum 60 bp, regions 5′
upstream (c.-136-1434 till c.-136-1, positions according to
GenBank NM_000371.3) and 3′downstream (c.*349 till c.
*349+79) including 14 single nucleotide polymorphisms
(SNP), rs3764478, rs71383038, rs72922940, rs3764477,
rs58616646, rs3794886, rs3794885, rs16962206,
rs1551005, rs1800458, rs28933979 (V30M), rs1061978 and
rs11541783, rs62093482 (SNPs according to NCBI and
Ensembl), were analysed by sequencing (table 1). In addi-
tion, 19 known intronic SNPs, rs9304103, rs7231173,
rs723744, rs1080093, rs1080094, rs17740912, rs58272364,
rs13381331, rs1791225, rs3764476, rs10707844,
ENSSNP11324634, rs7235277, rs3794884, rs1667250,
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Page 2 of 7rs1791226, rs1791227, rs1667251, rs59306196, with a
minimum flanking region of 50 bp surrounding each SNP
were also analysed by sequencing (table 1). In the French
and Japanese samples only SNPs significant in the Swedish
material were sequenced (table 1). PCR primer sequences
and PCR conditions are available on request. Each primer
was tailed with a universal M13 sequence and designed for
universal PCR and sequencing conditions. PCR amplifica-
tion was performed on a GeneAmp PCR System 9700
(Applied Biosystems) thermal cycler with AmpliTaq Gold
(PE Applied Biosystems, USA) in 10 μl reactions contain-
ing 15-20ng of genomic DNA. Bidirectional sequencing
was performed with dye terminator chemistry (Applied
Biosystems) according to the manufacturer’s instructions,
scaled down to 1/16 in a 10 μl reaction. Sequencing reac-
tions were electrophoresed on a 3730 × l DNA Analyzer
using POP-7™ (Applied Biosystems), data analyzed with
SeqScape Software v2.1 (ABI Prism, USA).
Statistics
To analyse differences in allele frequency between
patient/carrier and control groups Fisher’se x a c t
probability test was performed using InStat v3.06 for
Windows, GraphPad Software Inc. USA. All the
P-values presented in the paper refer to two-sided
T-test. P-values were also corrected for multiple testing
using the Bonferroni method. For non corrected statis-
tics a P-value ≤0.05 was considered significant, for
corrected statistics a P-value ≤0.003.
Ethics
T h es t u d yw a sa p p r o v e db yt h eE t h i c a lC o m m i t t e eo f
Umeå University, (Dnr 06-084M).
Results
In order to analyse differences in allele frequencies that
influence the phenotype of the disease with regards to
age at onset and penetrance, we compared allele fre-
quencies for all SNPs in Swedish FAP patients with
early onset and late onset, all FAP patients, asympto-
matic V30M carriers and all V30M carriers to controls.
Significant differences in allele frequency were only
detected when comparing all V30M carriers to controls.
In the Swedish material two novel polymorphisms were
found in the 5′upstream region (table 1). Neither of
these showed any significant difference in allele fre-
quency between V30M carriers and controls. Of the
known SNPs analysed, a variant allele was detected in
Table 1 SNPs in the TTR gene and the surrounding regions with polymorphisms present in the analysed Swedish
samples
Minor allele (frequency)
dsSNP ID Location NM_000371.3 (HGVS) Location Controls V30M Carriers P-value
a
rs3764478 c.-136-1247G > T 5’upstream T (0.09) T (0.07)
rs71383038 c.-136-1097_-1096delCA 5’upstream CA9 (0.31) CA9 (0.17) 0.0034
rs72922940 c.-136-1032A > G 5’upstream G (0.07) G (0.05)
rs3764477 c.-136-1021G > A 5’upstream A (0.00) A (0.01)
rs58616646 c.-136-1000C > T 5’upstream T (0.00) T (0.01)
* c.-136-697C > T 5’upstream T (0.03) T (0.01)
rs3794885 c.-136-607A > T 5’upstream T (0.32) T (0.18) 0.0041
* c.-136-546G > A 5’upstream A (0.02) A (0.03)
rs723744 c.70-383G > T intronic T (0.31) T (0.19)
rs1800458 c.76G > A, p.G26R exon 2 A (0.04) A (0.02)
rs28933979 c.148G > T, p.V50 M (V30M) exon 2 G (0.00) G (0.51)
rs1080093 c.200+691C > G intronic G (0.31) G (0.20)
rs1080094 c.200+806A > G intronic G (0.30) G (0.20)
rs3764476 c.336+1242C > A intronic A (0.30) A (0.20)
ENSSNP11324634 c.336+1432A > G intronic G (0.00) G (0.01)
rs7235277 c.336+1655G > C intronic C (0.37) C (0.18)
rs3794884 c.337-1560T > G intronic G (0.31) G (0.19)
rs36204272 c.337-18G > C intronic C (0.00) C (0.01)
rs62093482 c.*261C > T 3’UTR T (0.04) C (0.48) < 0.0001
b
SNPs with significant differences in allele frequencies between V30M carriers and controls are shown in bold. Previously not reported polymorphisms are marked
with a star (*).
aP-value ≤0.05 were considered statistical significant. P-value calculated by Fisher exact probability test.
bP-value significant after Bonferroni
correction (P-value ≤0.003).
For sixteen SNPs only the wt allele were detected in the Swedish material, these are not included in the table: rs3794886, rs16962206, rs1551005, rs9304103,
rs7231173, rs17740912, rs58272364, rs13381331, rs1791225, rs10707844, rs1667250, rs1791226, rs1791227, rs1667251, rs1061978, rs11541783.
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rs62093482 showed a significant difference in allele
frequency between V30M carriers and controls.
For SNP rs71383038 located upstream of the TTR
gene start (c.-136-1097_-1096delCA) the Swedish V30M
carriers showed a higher allele frequency of the major
(CA10) allele compared to the controls (P = 0.0034,
Table 1). The CA10 allele was present on at least one
chromosome in all heterozygous V30M carriers. The
two Swedish V30M homozygous patients present in the
material also displayed homozygosity for CA10, confirm-
ing that the Swedish V30M haplotype also contains the
CA10 allele. In the French patient material (a population
with several V30M founders), the CA9 and CA10 alleles
were evenly distributed and homozygosity for both
alleles was found. This was significantly different from
the French controls (P = 0.0015), where CA10 is more
prevalent. None of the Japanese patients displayed
homozygosity for CA9. However, no significant differ-
ence in the allele frequency of CA10 and CA9 was
noted between patients and controls, probably due to
limited sample size (n = 37).
For SNP rs3794885 located upstream of the TTR gene
start (c.-136 -607A > T) A was identified as the major
allele in the Swedish population. In addition, Swedish
V30M carriers showed a higher allele frequency of the
A allele compared to the controls (P = 0.0041, table 1).
In analogy with the CA10 allele discussed above, the A
allele is present on the V30M haplotype. However, for
rs3794885 one patient heterozygous for V30M is homo-
zygous for the T allele which is, likely explained either
by a recombination event or de novo mutation on the
original Swedish V30M haplotype. Also in the French
population A is the major allele for rs3794885. In con-
trast to Swedish patients, French patients showed an
overrepresentation of the T allele (P = 0.0058). The
Japanese samples did not display any significant differ-
ences in the distribution of A and T alleles between
patients and controls for rs3794885. This is probably
due to both the low frequency of the T allele (4%) in
this population and the small sample size.
For SNP rs62093482 located in the 3′UTR of the TTR
gene (c.*261C > T) C is the major allele in the Swedish
population (96%). However, Swedish V30M carriers
showed a significantly higher allele frequency of the T
allele compared to the controls (P < 0.0001, table 1). In
the Swedish population rs62093482 is the only SNP that
remains significant after correction for multiple testing.
Also the T allele of rs62093482 can be assigned to the
V30M haplotype. In the French population the allele
frequencies of rs62093482 were in concordance with
those of the Swedish population, yet the T allele was
not detected among any of the French patients. In the
Japanese population the T allele was not present at all.
microRNA target predictions of polymorphism
rs62093482
Previously published studies report that SNPs in the 3′
UTR can affect gene expression levels by modifying
miRNA targeting activity [12-15]. In this respect we
found the 3′UTR polymorphism rs62093482 of particu-
lar interest. To investigate the presence of putative
miRNA target sites that might be affected by this poly-
morphism, we analysed wild type (wt) and polymorphic
sequences of the TTR 3′UTR including the region c.*1-
c.*349 using the miRNA target prediction programs
MicroInspector 1.5 http://bioinfo.uni-plovdiv.bg/micro-
inspector/[16] and the PITA algorithm by Segal Lab of
Computational Biology http://genie.weizmann.ac.il/pubs/
mir07/mir07_prediction.html[17]. We identified a total
of five miRNAs with predicted target sites unique for
the wt (C) allele and four miRNAs that were unique for
the polymorphic T allele of rs62093482 (table 2). The
miRNA hsa-miR-643, predicted to be unique for the
polymorphic T allele, was the only miRNA to be identi-
fied using both MicroInspector and PITA. In an attempt
to substantiate the predictions made in MicroInspector
and PITA, we used RNAhybrid http://bibiserv.techfak.
uni-bielefeld.de/rnahybrid/[18] and RegRNA http://
regrna.mbc.nctu.edu.tw/[19] to cross analyse all nine
identified miRNAs. To minimize false positive predic-
tions we set up criteria that the predicted miRNA
targets should fulfil. To be regarded as a potential
miRNA target site, a predicted target site had to be
unique for the wt or polymorphic alleles, respectively, in
MicroInspector and/or PITA and also for this prediction
to hold true with both programs used for the subse-
quent validation procedure. Based on these criteria all
the identified miRNAs predicted to target wt 3′UTR
(hsa-miR-593, hsa-miR-492, hsa-miR-1245, hsa-miR-581
and hsa-miR-142-3p) and one of the identified miRNAs
predicted to target polymorphic 3′UTR (hsa-miR-384)
were excluded (table 2). Of the remaining four miRNAs,
all identified to be unique for the polymorphic 3′UTR,
hsamiR-622 is the only miRNA still unique for the poly-
morphic target after the validation in both RNAhybrid
and RegRNA. Regarding hsa-miR-643, hsa-miR-337-3p
and hsa-miR-325, first identified as unique for the poly-
morphic allele, RNAhybrid predicted a target on both
polymorphic and wt alleles (table 2). Based on thermo-
dynamic properties of the miRNA:mRNA hybridisation
analysed, the RNAhybrid predicted binding specificity to
the wt allele is substantially weaker than that to the
polymorphic allele, hence we still consider these miR-
NAs to be unique for the polymorphic allele.
Discussion
The previously published high V30M carrier frequency
(8.3%) in the Lycksele subregion of the Västerbotten
Olsson et al. BMC Medical Genetics 2010, 11:130
http://www.biomedcentral.com/1471-2350/11/130
Page 4 of 7County in Sweden [5] could not be repeated in our
study, which is based on a larger cohort. The actual car-
rier frequency of V30M in the Lycksele subregion was
2%. Our finding of 1.8% V30M carriers in our endemic
area in Västerbotten is close to the V30M mutation
frequency of 2.2% calculated from data reported from
Västerbotten County by Holmgren et al. [5], and it is
still 10 times higher than in Portugal.
The results for the SNP rs71383038 in the Swedish
material showed that CA10 is significantly associated to
V30M. This is similar to previous data from Portugal
where CA10 is associated with V30M [20]. Neither this
nor the other 5′upstream polymorphism (rs3794885)
also significant associated to the V30M allele can be
predicted to affect the binding of transcription factors
according to TFSEARCH, Searching Transcription
Factor Binding Sites (ver. 1.3) [21].
Our result show that the T allele of the 3′UTR poly-
morphism (rs62093482, positioned at c.*261) in all
Swedish V30M carriers has the capacity to serve as a
miRNA binding site. The miRNA target prediction tools
available today have improved their accuracy since the
first computational prediction program was developed
in 2003. Yet, in order to increase the validity of our
finding, we decided to use two different programs to
screen for all known human miRNA against our chosen
input target sequence (MicroInspector and PITA).
Thereafter, we re-analysed the putative miRNAs, pre-
dicted by the above mentioned computational programs
with two additional programs -RNAhybrid and RegRNA,
to ensure that our putative miRNAs were unique for wt
or polymorphic targets.
The miRNAs with predicted targets on the poly-
morphic allele that fulfilled our defined criteria were
hsa-miR-643, hsa-miR-337-3p, hsa-miR-622 and hsa-
miR-325. We consider hsa-miR-643 to be the best
predicted candidate after re-evaluation of RNAhybrid’s
predictions based on the thermodynamic properties.
That the rs62093482 T allele has the capacity to serve
as a miRNA binding site is especially intriguing since
recent data show that motifs in the 3′UTR can be
involved in gene regulation of certain genes via miRNA
repression. Since all Swedish V30M carriers also carries
this T allele we hypothesize that miRNA repression has
an impact on the expression of the TTR V30M allele by
partial silencing, which in turn could explain the low
penetrance and high age at onset of disease observed in
Swedish V30M carriers. Although the Swedish popula-
tion as a group has a low penetrance, differences within
the population still exists. The difference within the
Swedish population might be explained by other factors
such as differences in the regulation of the miRNA
itself. Since miRNA functions as translational repressor
and triggers mRNA degradation, one could expect
plasma TTR levels to be lowered in Swedish V30M car-
riers due to the polymorphic 3′UTR. Data supporting
this hypothesis was published earlier by Suhr et al. [22],
showing significantly lower total plasma TTR levels in
Swedish V30M carriers compared with Swedish con-
trols, as measured by mass spectrometry analysis. In
heterozygous TTR V30M carriers, variant TTR (V30M)
protein contributed to only 42% of total TTR protein
[22]. However, Westermark et al. were unable to find
differences in total TTR concentration in plasma
between Swedish V30M carriers and healthy controls in
a study that included six V30M carriers [23]. These
findings have been revised by Buxbaum et al. showing
that there is a difference between Swedish TTR V30M
carriers and controls, with higher TTR levels in controls
than in V30M carriers [24]. These findings are consis-
tent with studies from other populations that also
have investigated the concentrations of TTR in plasma;
Table 2 miRNA target predictions for rs62093482
wt (C) allele Identified with Predicted binding to wt allele Predicted binding to polymorphic allele
hsa-miR-593 MicroInspector RegRNA/RNAhybrid RegRNA/RNAhybrid
hsa-miR-492 MicroInspector RNAhybrid RNAhybrid
hsa-miR-1245 PITA RNAhybrid RNAhybrid
hsa-miR-581 PITA RegRNA/RNAhybrid RNAhybrid
a
hsa-miR-142-3p PITA RegRNA/RNAhybrid RNAhybrid
a
Polymorphic (T) allele Identified with Predicted binding to wt allele Predicted binding to polymorphic allele
hsa-miR-643 MicroInspector/PITA RNAhybrid
b RegRNA/RNAhybrid
hsa-miR-337-3p MicroInspector RNAhybrid
b RegRNA/RNAhybrid
hsa-miR-384 MicroInspector RegRNA/RNAhybrid RegRNA/RNAhybrid
hsa-miR-622 PITA RegRNA/RNAhybrid
hsa-miR-325 PITA RNAhybrid
b RegRNA/RNAhybrid
Underlined; predictions unique for wt or polymorphic target respectively in the subsequent validation procedure. In bold, miRNA target predictions that fulfil the
criteria.
aPredicted for polymorphic target with only slightly weaker binding, C:G > U:G.
bDecreased binding specificity when predicted to wt target leading to
reduced thermodynamic properties.
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of TTR than controls. However, none of the latter stu-
dies have measured the relative amounts of mutated
versus wild-type TTR in the same samples [24]. From
t h e s es t u d i e sw h e r eo n l yt o t a lp l a s m al e v e l so fT T R
were measured, no conclusion about the variant TTR
(V30M) levels can be drawn since TTR appears to have
a self regulatory system of gene expression. This is sup-
ported by data from a previous study where intravenous
administration of wt TTR to FAP patients resulted in
suppression of the variant TTR (V30M) production [25].
If such an auto-regulatory loop exists, that keeps plasma
TTR levels at a steady concentration, one can speculate
that also partial transcriptional silencing of one allele
(e.g. V30M due to the presence of allele specific miRNA
binding site) could lead to upregulation of the other
allele (wt) to maintain a stable total protein level. From
the literature it is known that plasma TTR levels are age
and sex dependent [26]. Therefore, patients and controls
must be age and gender matched for comparison of
TTR-concentration, and further studies are needed to
elucidate if variant TTR concentration varies between
V30M carriers and controls.
The effect of a miRNA on a target gene is dependent
on the expression pattern and levels of the miRNA in
different tissues. The expression patterns of the miRNAs
identified in our study are to the best of our knowledge
not described in the literature, and their respective
expressions in liver and other target tissues in FAP are
yet to be analysed. Future plans also include in vitro stu-
dies to evaluate the possibility of interaction between
the polymorphic 3′UTR of the TTR gene and the pre-
dicted miRNAs (hsa-miR-643, hsa-miR-337-3p, hsa-
miR-325 and hsa-miR-622) that fulfilled the criteria.
I nt h i ss t u d yw eh a v ef o c u s e don single-locus effects
by allele frequencies of the three SNPs. Soares et al. has
indicated that interactions among multiple-loci may
explain the differences in phenotype [27]. Therefore, a
multiple-loci analysis of our results together with ade-
quate candidate genes would be of interest to evaluate
the possibilities of gene-gene interactions relevant for
disease development.
Epigenetic factors such as oxidative stress have been
implicated in FAP as well as in other neurodegenerative
diseases. Studies have shown that oxidative stress is
increased in patients with amyloidosis [28,29], and in
vitro studies have demonstrated that oxidative stress
inhibits the initial rate and extent of amyloid fibril for-
mation of wild-type as well as V30M transthyretin [30].
Our present data of a predicted novel miRNA targeting
site adds to the already complex picture of FAP patho-
genesis, and might contribute to the phenotypic diver-
sity observed between V30M populations.
Conclusion
Our analysis is the first to show that the T allele of the
3′UTR polymorphism rs62093482, present in all Swedish
TTR V30M carriers, can serve as a miRNA binding site
possibly leading to a down regulation of mutant TTR
expression. This finding could be related to the low
penetrance and high age at onset of the disease observed
in the Swedish patient population.
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